ArticleJournal of prevention (2022)2025
Agreement Between Office-Based and Laboratory-Based Globorisk Models and their Prediction of Cardiovascular Diseases in Turkish Population: A Nationwide Cohort Study.
Article in Journal of prevention (2022), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globorisk is a country-specific risk prediction model that estimates 10-year cardiovascular disease (CVD) risk. This study aims to evaluate the agreement between different versions of Globorisk and their ability to predict CVD in a nationwide Turkish cohort. Baseline data from 5449 participants aged 40-74 were obtained from Türkiye Chronic Diseases and Risk Factors Survey 2011. Office- and laboratory-based Globorisk risk scores were calculated using age, gender, systolic blood pressure (SBP), current smoking status, body mass index (BMI), diabetes, and total cholesterol levels. Correlation and Bland-Altman analysis were employed to assess the agreement between 10-year risk scores. Multivariable logistic regression models were estimated with Globorisk variables to predict the presence of CVD over a 6-year follow-up period. Model calibration was performed. The study identified 515 incident CVD cases during the 6-year follow-up period. There was a strong positive correlation between 10-year Globorisk versions (r = 0.89). The limit of the agreement was narrower in males (- 6.11 to 6.89%) compared to females (- 7.01 to 7.73%). Age and systolic blood pressure were associated with 6-year CVD in both office- and laboratory-based models. The models showed similar discriminative performance (AUC: 0.68) and predictive accuracy (mean absolute error: 0.009) for 6-year CVD. Both Globorisk models were strongly correlated, had similar discrimination power and predictive accuracy. The office-based Globorisk can be used instead of the laboratory-based model, especially where resources are limited.
Indexed as
Identifiers
39676143What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.